90 related articles for article (PubMed ID: 16546757)
1. Benefit of tianeptine and morphine in a transgenic model of familial amyotrophic lateral sclerosis.
Chritin M; Savasta M; Besson G
Amyotroph Lateral Scler; 2006 Mar; 7(1):32-7. PubMed ID: 16546757
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic benefits of putrescine-modified catalase in a transgenic mouse model of familial amyotrophic lateral sclerosis.
Reinholz MM; Merkle CM; Poduslo JF
Exp Neurol; 1999 Sep; 159(1):204-16. PubMed ID: 10486188
[TBL] [Abstract][Full Text] [Related]
3. [Amyotrophic lateral sclerosis: recent insights from transgenic animal models with SOD1 mutations].
Aoki M
Rinsho Shinkeigaku; 2004 Nov; 44(11):788-91. PubMed ID: 15651292
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis.
Urushitani M; Ezzi SA; Julien JP
Proc Natl Acad Sci U S A; 2007 Feb; 104(7):2495-500. PubMed ID: 17277077
[TBL] [Abstract][Full Text] [Related]
5. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS.
Turner BJ; Talbot K
Prog Neurobiol; 2008 May; 85(1):94-134. PubMed ID: 18282652
[TBL] [Abstract][Full Text] [Related]
6. Combined immunosuppressive agents or CD4 antibodies prolong survival of human neural stem cell grafts and improve disease outcomes in amyotrophic lateral sclerosis transgenic mice.
Yan J; Xu L; Welsh AM; Chen D; Hazel T; Johe K; Koliatsos VE
Stem Cells; 2006 Aug; 24(8):1976-85. PubMed ID: 16644922
[TBL] [Abstract][Full Text] [Related]
7. The potential for the use of mononuclear cells from human umbilical cord blood in the treatment of amyotrophic lateral sclerosis in SOD1 mice.
Chen R; Ende N
J Med; 2000; 31(1-2):21-30. PubMed ID: 10998753
[TBL] [Abstract][Full Text] [Related]
8. Familial amyotrophic lateral sclerosis (FALS): Emerging hints from redox proteomics. Highlight commentary on: "Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice--a model of familial amyotrophic lateral sclerosis".
Dalle-Donne I
Free Radic Biol Med; 2007 Jul; 43(2):157-9. PubMed ID: 17603924
[No Abstract] [Full Text] [Related]
9. Regular exercise is beneficial to a mouse model of amyotrophic lateral sclerosis.
Kirkinezos IG; Hernandez D; Bradley WG; Moraes CT
Ann Neurol; 2003 Jun; 53(6):804-7. PubMed ID: 12783429
[TBL] [Abstract][Full Text] [Related]
10. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis.
Gurney ME; Cutting FB; Zhai P; Doble A; Taylor CP; Andrus PK; Hall ED
Ann Neurol; 1996 Feb; 39(2):147-57. PubMed ID: 8967745
[TBL] [Abstract][Full Text] [Related]
11. [Animal models of amyotrophic lateral sclerosis].
Yamanaka K
Rinsho Shinkeigaku; 2007 Nov; 47(11):934-7. PubMed ID: 18210840
[TBL] [Abstract][Full Text] [Related]
12. Evidence for secretion of Cu,Zn superoxide dismutase via exosomes from a cell model of amyotrophic lateral sclerosis.
Gomes C; Keller S; Altevogt P; Costa J
Neurosci Lett; 2007 Nov; 428(1):43-6. PubMed ID: 17942226
[TBL] [Abstract][Full Text] [Related]
13. Highlight Commentary on "Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice--a model of familial amyotrophic lateral sclerosis".
Calabrese V
Free Radic Biol Med; 2007 Jul; 43(2):160-2. PubMed ID: 17603925
[TBL] [Abstract][Full Text] [Related]
14. Transient caloric restriction in early adulthood hastens disease endpoint in male, but not female, Cu/Zn-SOD mutant G93A mice.
Hamadeh MJ; Tarnopolsky MA
Muscle Nerve; 2006 Dec; 34(6):709-19. PubMed ID: 16941656
[TBL] [Abstract][Full Text] [Related]
15. A transgenic-mouse model of amyotrophic lateral sclerosis.
Brown RH
N Engl J Med; 1994 Oct; 331(16):1091-2. PubMed ID: 8090173
[No Abstract] [Full Text] [Related]
16. Therapeutic benefit of polyamine-modified catalase as a scavenger of hydrogen peroxide and nitric oxide in familial amyotrophic lateral sclerosis transgenics.
Poduslo JF; Whelan SL; Curran GL; Wengenack TM
Ann Neurol; 2000 Dec; 48(6):943-7. PubMed ID: 11117554
[TBL] [Abstract][Full Text] [Related]
17. [ALS models by transgenic animals].
Aoki M; Nagai M; Kato M; Itoyama Y
No To Shinkei; 2001 Sep; 53(9):799-807. PubMed ID: 11596474
[No Abstract] [Full Text] [Related]
18. Therapeutic effects of CuII(atsm) in the SOD1-G37R mouse model of amyotrophic lateral sclerosis.
McAllum EJ; Lim NK; Hickey JL; Paterson BM; Donnelly PS; Li QX; Liddell JR; Barnham KJ; White AR; Crouch PJ
Amyotroph Lateral Scler Frontotemporal Degener; 2013 Dec; 14(7-8):586-90. PubMed ID: 23952668
[TBL] [Abstract][Full Text] [Related]
19. Superoxide dismutase and familial amyotrophic lateral sclerosis: new insights into mechanisms and treatments.
Brown RH
Ann Neurol; 1996 Feb; 39(2):145-6. PubMed ID: 8967744
[No Abstract] [Full Text] [Related]
20. Immunosuppressant FK506 does not exert beneficial effects in symptomatic G93A superoxide dismutase-1 transgenic mice.
Anneser JM; Gmerek A; Gerkrath J; Borasio GD; Heumann R
Neuroreport; 2001 Aug; 12(12):2663-5. PubMed ID: 11522944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
